213 results
Primary Objectives:The primary objective of this study is to characterize the effect of repeated oral administration of TAK-788 160 mgQD on the single oral- and IV-dose PK of midazolam.Secondary Objectives:The secondary objective of this study is to…
Primary Objectives:To determine the efficacy of brigatinib, as evidenced by confirmed objective response rate (ORR), in patients with ALK+ locally advanced or metastatic NSCLC whose disease has progressed on therapy with alectinib or ceritinib.…
The objective of the study is to give a dose of 45 to 60 Gy and therefore to prolong the survival in patients with recurrent lung cancer.
To determine FRAME-001-specific immune responses in peripheral blood after administration of FRAME-001 to patients with advanced NSCLC.Secondary objectives- To assess safety and tolerability of FRAME-001.- To evaluate clinical anti-tumor response to…
This study aims to prospectively evaluate the diagnostic properties and clinical value of the protein tumor markers CEA, CA15.3, Cyfra21.1, HE4, NSE, proGRP en SCC and the molecular tumormarkers EGFR, ALK, KRAS and BRAF in diagnosing, and monitoring…
Primary: 1. Effect of the highly potent CYP3A4 inhibitor ritonavir on the pharmacokinetics (PK) of erlotinib, measured as AUC0-24h, AUCmean, Cmax and CminSecondary objective 1. Safety of the CYP3A4 moderator ritonavir in combination with erlotinib,…
The main objective of this pilot study is to evaluate the effect of motion mitigation with BiPAP or CPAP on tumor motion during the course of radiotherapy in patients with intra-thoracic tumors.
A) To quantify the difference in 18F-FDG uptake (expressed as SUVmax, SUVmean and SUVpeak) in tumor lesions within 7 days before and between 7 and 14 days after treatment initiation with immune checkpoint inhibitors with or without chemotherapy. B)…
The overall aim of this study is to demonstrate increase of tumor-infiltrating CD8+ T cells in non-small cell lung cancer during neo-adjuvant treatment with durvalumab (MEDI4736).
To identify the immunological response to combined SABR and pembrolizumab treatment in early stage NSCLC. Expression rates andactivation states of immune effector subsets will be assessed in tumor core biopsy specimens, peripheral blood and tumor…
To study the diagnostic accuracy of FDG PET and MRI as a function of time in the response monitoring and detection of residual lymph node metastases after non-surgical treatment of advanced head and neck cancer.
Primary: • To assess the Major Pathological Response (MPR) rate (<= 10% of residual viable tumor cells) on the resected specimen at the time of surgery in all subjects randomized to canakinumab alone or in combination with pembrolizumab.…
To assess the progression-free survival rate at 12 months (PFSR12) to lorlatinib in ALK positive advanced NSCLC patients, who progressed on second generation ALK-TKI with the presence of ALK resistance mutations on blood (liquid biopsies) by…
To compare the objective response rate between patients with metastatic non-small cell lung cancer characterized by PDL-1 TPS<50% and low cTML (<300 nonsynonymous mutations) and either actionable mutation, inactivating STK11 or KEAP1…
We will measure correlations between serially measured MRI parameters (pretreatment and early during treatment) and therapy outcome (response, locoregional recurrence and overall survival) in patients with HNSCC undergoing chemoradiation (CRT)…
The primary objective of this study is to evaluate the clinical performance of the [Redacted] PD-L1 [Redacted] CDx Assay in terms of its ability to identify patients with non-squamous metastatic NSCLC (mNSCLC) who may benefit from treatment with […
Identify molecular differences in carcinogenesis of LSCC between younger and elderly patients through an integrated proteogenomic analysis of laryngeal tissue biopsies that could optimize personalized treatment of elderly patients in particular.
The primary objective is to assess the efficacy of alectinib in terms of best overall response (OR) assessed by RECIST v1.1. The secondary objectives are to evaluate secondary measures of clinical efficacy including disease control, progression-free…
The primary objective is to evaluate the antitumor activity of ceritinib in patients with ALK-positive NSCLC metastatic to the brain and/or toleptomeninges based on whole body overall response rate (ORR), defined as the proportion of patients with a…
The Imalife study aims to assess reference values of lung density, bronchial wall thickness, vascular calcification and lung nodules by quantitative low-dose CT. Secondarily, it aims to assess the relation of quantitative imaging biomarkers of the…